Related Experiment Video

Updated: Jun 11, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Nifedipine-induced changes in the electrohysterogram of preterm contractions: feasibility in clinical practice

Maartje P G C Vinken1, C Rabotti, M Mischi

  • 1Department of Obstetrics and Gynecology, Máxima Medical Centre, De Run 4600, 5504 DB Veldhoven, The Netherlands.

Obstetrics and Gynecology International
|July 9, 2010
PubMed

Objective. Evaluating changes in the power spectral density (PSD) peak frequency of the electrohysterogram (EHG) caused by nifedipine in women with preterm contractions. Methods. Calculation of the PSD peak frequency in EHG contraction bursts at different times of nifedipine treatment in women in gestational age 24 to 32 weeks with contractions. Results. A significant (P < .05) decrease of PSD peak frequency between EHG signals measured before and 15 minutes after administration of nifedipine. A significant (P < .05) decrease in PSD peak frequency comparing signals recorded within 24 hours after administration of nifedipine to signals 1 day after tocolytic treatment. A higher average PSD peak frequency for patients delivering within 1 week than that for patients delivering after 1 week from nifedipine treatment (P > .05). Conclusions. EHG signal analysis has great potential for quantitative monitoring of uterine contractions. Treatment with nifedipine leads to a shift to lower PSD peak frequency in the EHG signal.

More Related Videos

Electromyometrial Imaging of Uterine Contractions in Pregnant Women08:07

Electromyometrial Imaging of Uterine Contractions in Pregnant Women

Published on: May 26, 2023

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...